Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janelle Erickson

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Acta Dermato-Venereologica|October 18, 2019
Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical TrialLyn Guenther, Alison Potts Bleakman, Jamie Weisman, et al.
International Clinical Psychopharmacology|April 7, 2007
Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trialJames Hartford, Susan Kornstein, Michael Liebowitz, et al.
Lancet (London, England)|June 15, 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsChristopher E M Griffiths, Kristian Reich, Mark Lebwohl, et al.
The New England Journal of Medicine|June 15, 2016
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisKenneth B Gordon, Andrew Blauvelt, Kim A Papp, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Acta Dermato-Venereologica|October 18, 2019
Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical TrialLyn Guenther, Alison Potts Bleakman, Jamie Weisman, et al.
International Clinical Psychopharmacology|April 7, 2007
Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trialJames Hartford, Susan Kornstein, Michael Liebowitz, et al.
Lancet (London, England)|June 15, 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsChristopher E M Griffiths, Kristian Reich, Mark Lebwohl, et al.
The New England Journal of Medicine|June 15, 2016
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisKenneth B Gordon, Andrew Blauvelt, Kim A Papp, et al.
Pageof 2